http://purl.org/np/RA0Ki-qBZ2... RA0Ki-qBZ2

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom

https://dailymed.nlm.nih.gov/d...0a-c060-4d3e-ba41-763d791f63a9 drugInfo.cfm?setid=2731310a-c060-4d3e-ba41-763d791f63a9

Leoni Bücken

2021-04-03T10:26:50.920Z

http://purl.org/np/RA0Ki-qBZ2... RA0Ki-qBZ2

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/ns/prov#value value

RUZURGI is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age.

Leoni Bücken

2021-04-03T10:26:50.920Z

http://purl.org/np/RA0Ki-qBZ2... RA0Ki-qBZ2

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://purl.org/np/RA0Ki-qBZ2...#medtherapy medtherapy

http://www.w3.org/ns/prov#wasDerivedFrom wasDerivedFrom

Leoni Bücken

2021-04-03T10:26:50.920Z